DLL3 and neoplasm: Recently, tarlatamab, a bispecific TCE with a dual affinity for DLL3 on tumor cells and CD3 on T cells, showed impressive results in terms of antitumor activity, with durable objective responses and promising survival outcomes in patients with previously treated SCLC [53].